U.S. Markets closed
  • S&P 500

    3,443.12
    +16.20 (+0.47%)
     
  • Dow 30

    28,308.79
    +113.37 (+0.40%)
     
  • Nasdaq

    11,516.49
    +37.61 (+0.33%)
     
  • Russell 2000

    1,617.71
    +4.08 (+0.25%)
     
  • Crude Oil

    41.51
    +0.68 (+1.67%)
     
  • Gold

    1,910.30
    -1.40 (-0.07%)
     
  • Silver

    24.77
    +0.07 (+0.29%)
     
  • EUR/USD

    1.1830
    +0.0057 (+0.4850%)
     
  • 10-Yr Bond

    0.7970
    +0.0360 (+4.73%)
     
  • Vix

    29.35
    +0.17 (+0.58%)
     
  • GBP/USD

    1.2942
    +0.0002 (+0.0129%)
     
  • USD/JPY

    105.4640
    +0.0340 (+0.0322%)
     
  • BTC-USD

    11,909.35
    +852.34 (+7.71%)
     
  • CMC Crypto 200

    239.39
    +0.48 (+0.20%)
     
  • FTSE 100

    5,889.22
    +4.57 (+0.08%)
     
  • Nikkei 225

    23,567.04
    -104.09 (-0.44%)
     

J&J unit to start mid-stage COVID-19 vaccine trials in Spain

·1 min read
FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the NYSE in New York
FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the NYSE in New York

BARCELONA (Reuters) - Johnson & Johnson's <JNJ.N> Janssen unit will begin mid-stage trials of its COVID-19 vaccine in Spain on Monday, the programme's lead investigator said.

Alberto Borobia said 190 people would take part in the country's trials, which will take place in three hospitals and be concluded by Sept. 22.

The Spanish study is part of mid-stage, or Phase II, trials of the vaccine that are being carried out in three countries, also including the Netherlands and Germany. The trials in the three countries will last two months and include 550 participants in total.

(Reporting by Graham Keeley; Editing by Pravin Char)